. 2007 Mar 31;2(1):51–62.

Table 4.

Effect of etanercept on other disease-related outcomes in patients with psoriasis

Level of evidence	Reference	Design	Treatment	Outcomes
2^a	Nayak & Zitnik 2003; Gottlieb et al. 2004a	R, DB, MC, PC, 24-week study involving 31 patients^b	ETN 25 mg or 50 mg biw, or PLA	Skin biopsy samples taken from patients showed that clinical efficacy with ETN was associated with reductions in several markers of inflammation, including epidermal thickness, epidermal T-cell infiltration, and keratinocyte activation and proliferation
2	Mease et al 2000	R, DB, PC, 12-week study involving 38 patients (psoriasis ≥3% BSA involvement)	ETN 25 mg biw, or PLA	Median response of target lesion: 50% with ETN vs 0% with PLA (P=0.0004)
3	Jacob et al. 2005	CS, chart review of 53 patients treated with ETN	ETN in patients for whom traditional systemic treatments had failed to control psoriasis	50% of patients achieved PGA ≥3, 73.5% patients discontinued or decreased previous systemic therapies, and maintained their PGA score with ETN
3^a	Elewski et al. 2005	OL extension of phase III studies	ETN 25 mg biw switched to 50 mg qw for 12 weeks in OL extension	Mean PASI score at start of OL (5.77) was maintained by switch to ETN 50 mg (5.82, P=0.76) A similar proportion of patients achieved DGA “clear/almost clear” status with ETN 25 mg (43%) vs ETN 50 mg (38%) Comparable pharmacokinetic profile for both dosing regimens

Abstract.

Substudy of Gottlieb et al. 2003.

Leonardi et al. 2003 and Papp et al. 2005.

biw, twice weekly; BSA, body surface area; CS, cohort study; DB, double-blind; DGA, Dermatologist Global Assessment of psoriasis; ETN, etanercept; MC, multicenter; OL, open-label; PASI, Psoriasis Area and Severity Index; PC, placebo-controlled; PGA, Physician’s static Global Assessment of psoriasis; PLA, placebo; R, randomized; qw, once weekly.